Cargando…

Attenuated androgen discontinuation in patients with hereditary angioedema: a commented case series

BACKGROUND: Hereditary angioedema (HAE) is characterized by potentially severe and life-threatening attacks of localized swelling. Prophylactic therapies are available, including attenuated androgens. Efficacy of attenuated androgens has not been assessed in large, randomized, placebo-controlled tri...

Descripción completa

Detalles Bibliográficos
Autores principales:	Maurer, Marcus, Magerl, Markus, Aygören-Pürsün, Emel, Bork, Konrad, Farkas, Henriette, Longhurst, Hilary, Kiani‑Alikhan, Sorena, Bouillet, Laurence, Boccon-Gibod, Isabelle, Cancian, Mauro, Zanichelli, Andrea, Launay, David
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8759255/ https://www.ncbi.nlm.nih.gov/pubmed/35027083 http://dx.doi.org/10.1186/s13223-021-00644-0

Ejemplares similares

WAO Guideline for the Management of Hereditary Angioedema
por: Craig, Timothy, et al.
Publicado: (2012)

The Global Registry for Hereditary Angioedema due to C1-Inhibitor Deficiency
por: Zanichelli, Andrea, et al.
Publicado: (2021)

Hereditary angioedema with C1 inhibitor deficiency: delay in diagnosis in Europe
por: Zanichelli, Andrea, et al.
Publicado: (2013)

Management of patients with hereditary angioedema in Germany: comparison with other countries in the Icatibant Outcome Survey
por: Maurer, M., et al.
Publicado: (2018)

Epidemiology of Bradykinin-mediated angioedema: a systematic investigation of epidemiological studies
por: Aygören-Pürsün, Emel, et al.
Publicado: (2018)

The international WAO/EAACI guideline for the management of hereditary angioedema – The 2021 revision and update
por: Maurer, Marcus, et al.
Publicado: (2022)

Hereditary angioedema with normal C1 inhibitor in a French cohort: Clinical characteristics and response to treatment with icatibant
por: Bouillet, Laurence, et al.
Publicado: (2017)

Socioeconomic burden of hereditary angioedema: results from the hereditary angioedema burden of illness study in Europe
por: Aygören-Pürsün, Emel, et al.
Publicado: (2014)

Improvement in diagnostic delays over time in patients with hereditary angioedema: findings from the Icatibant Outcome Survey
por: Zanichelli, Andrea, et al.
Publicado: (2018)

Canadian hereditary angioedema guideline
por: Betschel, Stephen, et al.
Publicado: (2014)

Comparing acquired angioedema with hereditary angioedema (types I/II): findings from the Icatibant Outcome Survey
por: Longhurst, H. J., et al.
Publicado: (2017)

On demand treatment and home therapy of hereditary angioedema in Germany - the Frankfurt experience
por: Aygören-Pürsün, Emel, et al.
Publicado: (2010)

Evaluation of patient‐reported outcome measures for on‐demand treatment of hereditary angioedema attacks and design of KONFIDENT, a phase 3 trial of sebetralstat
por: Cohn, Danny M., et al.
Publicado: (2023)

Long‐term safety and effectiveness of berotralstat for hereditary angioedema: The open‐label APeX‐S study
por: Farkas, Henriette, et al.
Publicado: (2021)

Hereditary Angioedema Attacks Resolve Faster and Are Shorter after Early Icatibant Treatment
por: Maurer, Marcus, et al.
Publicado: (2013)

Effectiveness of icatibant for treatment of hereditary angioedema attacks is not affected by body weight: findings from the Icatibant Outcome Survey, a cohort observational study
por: Caballero, Teresa, et al.
Publicado: (2018)

Breakthrough attacks in patients with hereditary angioedema receiving long-term prophylaxis are responsive to icatibant: findings from the Icatibant Outcome Survey
por: Aberer, Werner, et al.
Publicado: (2017)

The Icatibant Outcome Survey: treatment of laryngeal angioedema attacks
por: Longhurst, Hilary J., et al.
Publicado: (2016)

Profile of serious angioedema requiring an urgent advice from a national reference call center
por: Simon, Nicolas, et al.
Publicado: (2022)

Hereditary Angioedema Caused By C1-Esterase Inhibitor Deficiency: A Literature-Based Analysis and Clinical Commentary on Prophylaxis Treatment Strategies
por: Gower, Richard G, et al.
Publicado: (2011)

Estimation of EuroQol 5-Dimensions health status utility values in hereditary angioedema
por: Aygören-Pürsün, Emel, et al.
Publicado: (2016)

Individual approach to long-term therapy in patients with hereditary angioedema (HAE-C1-INH): A case series
por: Andarawewa, S., et al.
Publicado: (2022)

549 Management of Twenty-Five Pediatric Patients with Hereditary Angioedema (Hae) Undergoing Home Treatment—A Clinical Surveillance Program
por: Martinez-Saguer, Inmaculada, et al.
Publicado: (2012)

The hereditary angioedema burden of illness study in Europe (HAE-BOIS-Europe): background and methodology
por: Bygum, Anette, et al.
Publicado: (2012)

Elderly versus younger patients with hereditary angioedema type I/II: patient characteristics and safety analysis from the Icatibant Outcome Survey
por: Bygum, Anette, et al.
Publicado: (2019)

Measurement of Bradykinin Formation and Degradation in Blood Plasma: Relevance for Acquired Angioedema Associated With Angiotensin Converting Enzyme Inhibition and for Hereditary Angioedema Due to Factor XII or Plasminogen Gene Variants
por: Marceau, François, et al.
Publicado: (2020)

The International/Canadian Hereditary Angioedema Guideline
por: Betschel, Stephen, et al.
Publicado: (2019)

Evaluation of avoralstat, an oral kallikrein inhibitor, in a Phase 3 hereditary angioedema prophylaxis trial: The OPuS‐2 study
por: Riedl, M. A., et al.
Publicado: (2018)

Expert perspectives on hereditary angioedema: Key areas for advancements in care across the patient journey
por: Banerji, Aleena, et al.
Publicado: (2016)

Correction to: The International/Canadian Hereditary Angioedema Guideline
por: Betschel, Stephen, et al.
Publicado: (2020)

The Icatibant Outcome Survey: experience of hereditary angioedema management from six European countries
por: Caballero, T., et al.
Publicado: (2017)

Hereditary angioedema in women
por: Bouillet, Laurence
Publicado: (2010)

Editorial: C1 inhibitor deficiency and angioedema
por: Farkas, Henriette, et al.
Publicado: (2022)

Clinical characteristics and burden of illness in patients with hereditary angioedema: findings from a multinational patient survey
por: Mendivil, Joan, et al.
Publicado: (2021)

Patient‐physician interactions in hereditary angioedema—Key learnings from the coronavirus disease 2019 pandemic
por: Maurer, Marcus, et al.
Publicado: (2023)

Management of acute attacks of hereditary angioedema: potential role of icatibant
por: Longhurst, Hilary J
Publicado: (2010)

Treatment of hereditary angioedema—single or multiple pathways to the rescue
por: Valerieva, Anna, et al.
Publicado: (2022)

Dedicated call center (SOS-HAE) for hereditary angioedema attacks: study protocol for a randomised controlled trial
por: Javaud, Nicolas, et al.
Publicado: (2016)

Elevated D-dimers in attacks of hereditary angioedema are not associated with increased thrombotic risk
por: Reshef, A, et al.
Publicado: (2015)

A randomized trial of human C1 inhibitor prophylaxis in children with hereditary angioedema
por: Aygören‐Pürsün, Emel, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_4ccs57ordiedmffcmuduhrta26